Gaisce Biosciences — Effective outpatient CAR-T for solid tumours

The moat / 01

Four barriers have kept
CAR-T out of solid tumours.

Each has its own well-documented failure mode. Gaisce engineers an answer to all four — trafficking, infiltration, persistence and safety — inside a single cell.

B-01

Trafficking

Failure mode Engineered cells never reach the tumour bed.

Gaisce A navigation system that directs the cell toward the tumour.
B-02

Infiltration

Failure mode The hostile microenvironment locks cells out.

Gaisce A solid-tumour breaker that gets inside and survives entry.
B-03

Persistence

Failure mode Cells exhaust and disappear before the job is done.

Gaisce Intrinsic durability that sustains activity over time.
B-04

Safety

Failure mode Toxicity forces costly inpatient management.

Gaisce Autonomous safety designed for the outpatient setting.

The platform / 02

One engineered cell.
Three systems.

We don’t bolt on a single fix. The platform integrates manufacturing, navigation and safety into one cell — each system addressing a different barrier, together making outpatient solid-tumour therapy feasible.

S-01

Bibac™

The launch vehicle

Non-viral, large-payload manufacturing — the vehicle that carries the full engineered package into the cell.

Biologic economics, not service economics.

S-02

STNAV™

The solid-tumour breaker

Homing, infiltration and survival, integrated into one navigation system that finds the tumour and gets inside.

A tumour-agnostic homing engine.

S-03

Stayble‑T™

The market unlock

Autonomous safety and intrinsic durability — the combination that moves treatment toward the outpatient setting.

Engineered to be outpatient-ready.

Lead construct / 03

A receptor chosen for breadth.
A signal chosen for tolerability.

Our lead construct is tumour-agnostic; our first target indication will be second-line and later metastatic colorectal cancer. It pairs broad, multi-ligand recognition with a signalling architecture selected for a cleaner tolerability profile than first-generation designs.

These are engineering decisions, not claims — each one made against a named failure mode, and each one carried forward only when the data clears our bar.

How we de-risk

Credibility / 04

Tier-1 science incubated inside
Tier-1 academic infrastructure.

€40M Research centre integrated

4/7 Commercial CAR-T delivered by our team

0 Barriers solved in one cell

1 Construct carrying the platform

We are not learning cell
therapy on this asset.

Building the navigation system for solid-tumour cell therapy — measured, evidence-grounded, and engineered end to end.

Investor enquiries Our approach

Four barriers have keptCAR-T out of solid tumours.

Trafficking

Infiltration

Persistence

Safety

One engineered cell.Three systems.